FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FENNEC PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.27+0.29 (+2.91%)
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.03 (+24.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
FENNEC PHARMACEUTICALS INC. grew revenue 77.8% to $59.22M over the twelve months to Jun 30, 2026.
Revenue
$59.22M
+77.8% vs. a year earlier
Operating income
-$1.13M
TTM Q2 2026
EPS, diluted
-$0.11
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $374.14M
- P/E ratio
- –
- Price to sales
- 6.32
- Price to book
- 8.82
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $59.22M
- Net income
- -$3.25M
- EPS, diluted
- -$0.11
- Book value per share
- $1.17
- Diluted shares
- 36M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$59.22M+77.8% YoY
Gross profit
–
Operating income
-$1.13M
Net income
-$3.25M
EPS, diluted
-$0.11
Free cash flow
–
Reported periodTrailing twelve months